Site Editor

David S. Ettinger, MD, FACP, FCCP

Advertisement
Advertisement

FDA Brief: Companion Diagnostic Approved for Tyrosine Kinase Inhibitor Treatment of NSCLC

By: JNCCN 360 Staff
Posted: Thursday, December 22, 2022

On December 21, Foundation Medicine announced that the U.S. Food and Drug Administration (FDA) has approved its FoundationOne®Liquid CDx as a companion diagnostic to identify patients with non–small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 L858R substitutions and are appropriate for treatment with a group of current and future EGFR tyrosine kinase inhibitors approved by the FDA for this indication. For prescription use only, this next-generation sequencing–based, in vitro diagnostic test employs targeted high throughput hybridization–based capture technology to analyze 324 genes using circulating cell-free DNA isolated from plasma derived from anticoagulated peripheral whole blood of patients with advanced cancer.

The current therapies for which FoundationOne Liquid CDx is a companion diagnostic under the group approvals are erlotinib, osimertinib, and gefitinib. Moving forward, FoundationOne Liquid CDx will automatically become a companion diagnostic for future tyrosine kinase inhibitors within this group for the treatment of NSCLC that are approved by the FDA.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.